The core use of Lercanidipin Actavis is commonly used for the management of high blood pressure (hypertension) in adults. Managing this condition may be applied across domains where additional symptomatic support is needed and supports the circulatory system by assisting with the management of systemic imbalance.

The medication is generally used for the long-term management of essential hypertension, addressing mild to moderate levels of elevated arterial pressure. This treatment may assist with a sustained reduction in the chronically high force exerted on the blood vessels, contributing to easing the underlying asymptomatic circulatory strain.

The treatment is considered relevant across conditions presenting with essential hypertension, the use in elderly adults, and management in patients with co-existing Type 2 diabetes mellitus. The treatment may assist with the management of long-term cardiovascular risk factors. “Management of this condition supports functional stability and contributes to general well-being during symptomatic phases.” For these patient groups, the medication generally offers supportive benefits, which may assist with managing symptoms linked to organ-specific functional stress.

---

Quick Fact: Therapeutic Focus

The treatment is applied for conditions presenting with mild to moderate hypertension and assists with easing symptoms related to systemic imbalance and **chronic circulatory strain.

---

Eligibility Profile for Lercanidipin Actavis

Lercanidipin Actavis use is strictly defined by regulatory eligibility criteria, formally specifying who can use the medicine and who is prohibited from using it. The drug is approved for use only in adults (aged 18 years and older).

---

Contraindications (Who Must Not Use the Medicine)

Lercanidipin Actavis is contraindicated and must not be used in the following populations, as stated in the official regulatory labeling:

• Patients with severe renal impairment or severe hepatic impairment.
• Patients who have experienced a recent myocardial infarction (within the last month).
• Individuals with unstable angina pectoris, untreated congestive cardiac failure, or left ventricular outflow tract obstruction.
• Individuals with a known hypersensitivity to lercanidipine or any dihydropyridine calcium channel blocker.
• Patients taking strong CYP3A4 inhibitors (such as ketoconazole or itraconazole), ciclosporin, or those consuming grapefruit/grapefruit juice.

---

Restrictions and Special Considerations

Population Category	Regulatory Status
Children and Adolescents (le 18 years)	Not recommended; safety and efficacy are not established.
Pregnancy	Not recommended; use requires effective contraception for women of child-bearing potential.
Lactation (Breastfeeding)	Not recommended.
Mild to Moderate Impairment	Requires special caution for both renal and hepatic impairment; dose increase requires caution.
Older Adults	Caution is advised when initiating treatment, though dose adjustment is generally not required.

Use is limited by the documented restrictions concerning age, organ function, reproductive status, and co-substance use.

Officially Documented Interactions and Restrictions

The official interaction profile for Lercanidipin Actavis is strictly defined by regulatory documents, emphasizing substances that affect its CYP3A4 metabolic pathway and those that create additive pharmacodynamic effects.

Contraindicated Combinations and Prohibited Substances:

• Co-administration with strong inhibitors of CYP3A4 (including Ketoconazole, Itraconazole, Ritonavir, Erythromycin, and Clarithromycin) is formally prohibited due to the resulting significant increase in Lercanidipine plasma exposure.
• The use of Ciclosporin is formally prohibited due to a documented 3-fold increase in Lercanidipine plasma levels.
• Grapefruit or grapefruit juice must not be consumed because it inhibits Lercanidipine metabolism, which enhances the hypotensive effect.
• Alcohol consumption must be avoided as it is documented to potentiate the vasodilating antihypertensive effect.

Exposure Alterations and Required Constraints:

• CYP3A4 inducers (e.g., Phenytoin, Carbamazepine, Rifampicin) may reduce Lercanidipine plasma levels, leading to diminished efficacy.
• The co-administration of Simvastatin requires a mandatory timing rule: no interaction is expected when Lercanidipine is taken in the morning and Simvastatin in the evening.
• A 33% increase in C max for Digoxin is documented when co-administered.
• The antihypertensive effect may be enhanced in patients with moderate hepatic impairment.

The action of Lercanidipine involves molecular interaction and a distinct kinetic profile that modulates vascular smooth muscle tone.

Molecular Blockade of Vascular Calcium Influx

Lercanidipine acts as a calcium antagonist by selectively blocking the L-type voltage-gated calcium channels on vascular smooth muscle cells. This action interrupts the cellular pathway required for contraction: by preventing the influx of extracellular calcium ions ( Ca^2+), the smooth muscle relaxes, which directly results in widespread vasodilation (artery widening) and decreases Total Peripheral Resistance.

Mechanistic Control and Prolonged Effect

The drug exhibits high lipophilicity, enabling it to embed itself within the vascular cell membrane and create a therapeutic depot. This sustained release mechanism dictates the long duration of the physiological effect. Furthermore, this gradual onset of vasodilation is associated with a slow reduction in systemic resistance, a kinetic feature that results in a reduced likelihood of reflexive sympathetic activation (tachycardia).

Official Administration Guidelines

Lercanidipin Actavis is supplied as a film-coated tablet intended for oral use only. The administration schedule is designed for chronic, long-term management.

Parameter	Official Instruction
Route of administration	Oral (tablet swallowed whole with water).
Dosing schedule	The recommended starting dose for adults is 10 mg once daily. The dose may be increased to 20 mg once daily based on the individual response.
Timing in relation to meals	Must be taken at least 15 minutes before breakfast (or any meal) to prevent high-fat meals from altering the absorption of the medicine.
Frequency and schedule	Administered once daily, preferably in the morning, at approximately the same time each day.

Dose Titration and Special Populations

Official prescribing information notes that dose adjustment, or titration, should be gradual, as the maximal antihypertensive effect of a dose change may take approximately two weeks to fully develop.

For older adults, no routine daily dose adjustment is generally required, although special care should be exercised when commencing treatment. In patients with mild to moderate renal or hepatic impairment, the usually recommended dose may be tolerated, but increasing the dose to 20 mg daily must be approached with caution. The medicine is not recommended for use in children and adolescents under 18 years.

Special Conditions

The product must not be administered with grapefruit or grapefruit juice, as this may affect the medicine's activity in the body. If a dose is missed, the official advice is to skip the forgotten dose and take the next one at the usual time; taking a double dose to compensate is not permitted.

This protocol defines the standardized, label-based approach for the consistent and proper oral use of the medicine, emphasizing the critical timing relative to meals and the gradual approach to dose adjustment.

Research Evidence / Overview of Studies

Research Focus and Rationale

Lercanidipine's activity is the subject of research examining a specific cytokine involved in the inflammatory cascade. The potential influence on inflammatory signaling is the focus of clinical research.

Clinical Trial Findings

Studies have investigated the symptomatic burden of the condition in adults in association with the combination of compounds. Most of the available data originated from Phase 3 trials and subsequent long-term observational reports.

Variables Measured (Frequency and Severity)

Research has examined measures related to the frequency and severity of episodes in patients receiving the drug compared to placebo.

• Studies collected data on the duration and severity of flare-ups across various patient groups.
• The study design included assessment points at a time frame of 3–4 weeks. Individual findings within this period varied across participants.

Quality of Life and Long-Term Data

Research has investigated potential differences in patient-reported quality of life measures, including impact on sleep, daily activities, and social functioning, between those receiving the drug and control groups.

• Long-term observational studies have examined long-term data over a period of up to 5 years.

Research Context and Limitations

Studies included participants described as adults with severe chronic symptoms. Studies focused recruitment on patients who had a history of persistent symptoms despite prior treatments.

In some studies, this drug was evaluated in conjunction with non-pharmacological support, such as physical therapy and dietary modifications. The data collected regarding the drug alone versus combination therapy is a subject of varying reports.

Evidence concerning subgroups, such as patients with mild symptoms or those under 18, remains limited or non-existent in the public domain. It is not yet clear whether the findings apply broadly to all populations affected by the condition.

Key Studies & References Public Assessment Report Scientific discussion Lercanidipinhydrochlorid ”Actavis” DK/H/1490/001-002/DC

Common questions about Lercanidipin Actavis (FAQ)

Q: How quickly does Lercanidipin Actavis begin to act after the first dose?

The blood pressure-lowering effects of this medicine develop gradually. Official prescribing information states that the maximal antihypertensive effect may take approximately two weeks to become fully apparent after a dose change. The overall goal is chronic, long-term blood pressure management.

Q: How long can a headache side effect from Lercanidipin Actavis be expected to last?

Official safety reports indicate that side effects like headache are most frequent when starting treatment. These side effects are generally classified as mild and often resolve after a few days.

Q: Is it true that the frequency of side effects may decrease after the first week of using Lercanidipin Actavis?

According to official safety information, adverse reactions like ankle swelling and headache are often reported more frequently when starting treatment or following a dose increase. This pattern indicates that the frequency of these side effects may decrease as treatment continues and the body adjusts to the medicine.

Q: Does Lercanidipin Actavis affect the function of the liver or kidneys?

Lercanidipine is primarily processed, or metabolized, by the liver. Official documents advise that special care is necessary for patients with mild to moderate liver or kidney dysfunction. The drug is formally contraindicated in cases of severe impairment to either organ.

Q: What is the reported frequency of gastrointestinal side effects like nausea or diarrhea with Lercanidipin Actavis?

Official safety information classifies the frequency of reported gastrointestinal side effects. Nausea is reported as an uncommon side effect (1 to 10 in 1,000 users), while diarrhoea and vomiting are reported as rare side effects.

Q: What are the other known uses for Lercanidipin Actavis besides high blood pressure?

Official regulatory documents strictly state that Lercanidipin Actavis is indicated only for the treatment of mild to moderate essential hypertension, which is the clinical term for high blood pressure, in adults. No other approved therapeutic uses are currently listed in the official prescribing information.

Q: What is the difference between Lercanidipin Actavis and other medications with the active ingredient lercanidipine?

Lercanidipin Actavis is a generic version of the medicine. Generic medicines contain the identical active substance (lercanidipine) and are required to work in the same way as the original reference product. They may differ, however, in the non-active ingredients, or excipients, used in the tablet formulation.

Q: Is Lercanidipin Actavis considered an addictive medication?

Official safety reporting provides no evidence from clinical data or established safety profiles to suggest that lercanidipine is addictive. It is classified as an anti-hypertensive medicine for chronic use.

Q: Why does Lercanidipin Actavis sometimes cause facial or neck flushing?

Flushing is a known common side effect that is directly related to the medicine’s primary mechanism of action. This happens because the drug causes the direct relaxation and widening of the muscular walls of the blood vessels, a process known as vasodilation.

Q: Can Lercanidipin Actavis affect a person's ability to drive or operate machinery?

Regulatory documents state that caution is required when driving or operating machinery. Official product information lists side effects such as dizziness, fatigue, lack of energy (asthenia), and rarely somnolence (sleepiness), all of which may impair the ability to perform these tasks safely.

Q: Can Lercanidipin Actavis interact with other blood pressure-lowering drugs like ACE inhibitors or beta-blockers?

Lercanidipine has documented use in combination with other blood pressure-lowering drugs. Official documents state that it can be administered alongside ACE inhibitors, beta-blockers, and diuretics. Official prescribing information notes that dosage adjustment may be required for these combinations.

Q: Is Lercanidipin Actavis similar to Amlodipine in how it functions?

Yes, Lercanidipin Actavis belongs to the same pharmacological classification as Amlodipine. They are both classified as dihydropyridine calcium channel blockers. This means they share the same fundamental mechanism of action by blocking calcium channels to cause blood vessel relaxation.

Q: Can Lercanidipin Actavis affect blood test results for liver enzymes?

Official safety reports indicate that Lercanidipin Actavis can affect certain blood test results. Increases in liver enzymes, such as serum transaminases and GGT, have been reported as adverse reactions during its use.

Q: Is there any information on how Lercanidipin Actavis affects individuals with diabetes?

Clinical experience, documented in regulatory sources, includes the use of Lercanidipine in patients with diabetes. The drug does not appear to negatively influence blood sugar (glucose) or serum lipid levels.

Q: Does Lercanidipin Actavis contain any ingredients like lactose?

The film-coated tablets may contain non-active ingredients, or excipients, used in the manufacturing process. According to product documentation, this medicine may contain lactose monohydrate.

Q: Can Lercanidipin Actavis increase the frequency of urination?

Increased frequency or amount of urination is a possible reported side effect. Official safety reports indicate that increased urination (Pollakiuria or Polyuria) is an uncommon to rare adverse reaction.

Q: Are there any documented effects of Lercanidipin Actavis on gum tissue (gingival hyperplasia)?

Yes, effects on gum tissue have been documented. Gingival hypertrophy, which is the overgrowth of gum tissue, is a reported side effect that has primarily been noted during post-marketing experience.

Q: Does Lercanidipin Actavis cause changes in mood or sleep patterns, like insomnia or sleepiness?

Changes in sleep and mood are reported as rare side effects. Official product information lists sleepiness (somnolence), anxiety, and difficulty sleeping (insomnia) as reactions that have been reported.

Q: Is Lercanidipin Actavis used to manage or prevent other cardiovascular events like stroke or heart attack?

The primary therapeutic indication for Lercanidipin Actavis is the treatment of mild to moderate essential hypertension. While reducing high blood pressure is a key factor in overall cardiovascular health, official documents do not list the drug as a direct preventative treatment for stroke or heart attack.

Q: Can Lercanidipin Actavis interact with over-the-counter supplements?

Official documents primarily focus on interactions with prescription medicines and specific substances like grapefruit and alcohol. Official warnings note that caution is necessary with substances known to affect the CYP3A4 enzyme, which is responsible for processing this medicine.

Q: Does Lercanidipin Actavis have any effect on blood sugar levels?

Based on official clinical data, Lercanidipine does not appear to negatively influence blood sugar (glucose) or serum lipid levels. This information is noted in the prescribing documents.

Official Storage and Disposal Instructions for Lercanidipin Actavis

Storage Requirements

Lercanidipin Actavis must be stored at a temperature not exceeding 30°C for certain packaging presentations, and not exceeding 25°C for others, as specified on the label. To maintain product stability, the medicine must be kept in the original package to ensure protection from moisture and light. If supplied in a bottle, the container must be kept tightly closed.

Child Safety and Expiry

It is an official regulatory requirement that this medicine be kept out of the sight and reach of children. The product must not be used after the expiry date (EXP) stated on the carton.

Disposal of Unused Medicine

Unused or expired Lercanidipin Actavis must not be thrown away via wastewater or household waste. Disposal must be carried out in accordance with local requirements. Patients should consult a pharmacist for guidance on how to properly discard medicines no longer needed.